2006
DOI: 10.4049/jimmunol.177.10.6974
|View full text |Cite
|
Sign up to set email alerts
|

Antibodies to Complement Receptor 3 Treat Established Inflammation in Murine Models of Colitis and a Novel Model of Psoriasiform Dermatitis

Abstract: Prior studies indicated the ability of Abs to complement receptor 3 (CR3, CD11b/CD18) to suppress the production of IL-12 from immune cells. Therefore, we tested the ability of an anti-CR3 Ab (clone M1/70) to treat established IL-12-dependent Th1-mediated inflammation in murine models. Systemic administration of anti-CR3 significantly ameliorated established intestinal inflammation following the intrarectal administration of trinitrobenzene sulfonic acid (TNBS-colitis), as well as colitis and skin inflammation… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
37
0

Year Published

2007
2007
2020
2020

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 43 publications
(40 citation statements)
references
References 44 publications
3
37
0
Order By: Relevance
“…Clearly, immune cells can trigger this crosstalk, as shown by the induction of psoriasiform, inflammatory skin lesions in mice by transfer of CD4+CD45RBhi T cells into T cell deficient Rag22/2 mice (Leon et al, 2006). However, also keratinocytes are able to initiate immune system activation.…”
Section: Discussionmentioning
confidence: 99%
“…Clearly, immune cells can trigger this crosstalk, as shown by the induction of psoriasiform, inflammatory skin lesions in mice by transfer of CD4+CD45RBhi T cells into T cell deficient Rag22/2 mice (Leon et al, 2006). However, also keratinocytes are able to initiate immune system activation.…”
Section: Discussionmentioning
confidence: 99%
“…Nonetheless, our data do not in any way diminish the possibility of using artificial ligation of CR3 as a means of manipulating DC function, because supraphysiologic activation of CR3 can clearly modulate DCs toward an anti-inflammatory phenotype (8 -10). Data already exist to suggest that the activation of CR3 via mAb may be useful in treating psoriasis and inflammatory colitis in mouse models of these diseases (42). However, it is important to put the role of CR3 in a physiologic context with respect to apoptotic cell processing and continuing to study the physiologic roles of CR3 will help us to understand how to best pursue its potential pharmacologic utility.…”
Section: Discussionmentioning
confidence: 99%
“…21,39 To determine whether phagocytosis of DAF/Crry-deficient platelets was mediated by these receptors, we transfused DAF/Crry-deficient platelets into mice that lacked functional CR3 or CRIg as a result of antibody blocking or gene deletion. 21,22,40,41 As shown in Figure 4E, antibody blocking of CR3 in WT mice or genetic disruption of CR3 (CD11b gene knockout) had no effect on the accelerated elimination of DAF/Crry-deficient platelets. Moreover, antibody blocking of CR1/2 in WT mice or CR4 in CR3 Ϫ/Ϫ mice did not rescue the transfused DAF/Crry-deficient platelets.…”
Section: Phagocytosis Of Daf/crry-deficient Platelets Was Mediated Bymentioning
confidence: 99%